{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-064560","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.976213+00:00","generated_at":"2026-06-12T03:28:55.010094+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nektar Therapeutics Q2 net loss narrows to $51.1M; cash $409.4M, runway into mid-2026","bullets":["Net loss $51.1M ($0.27/shr) vs $159.1M loss in Q2 2022; revenue $20.5M vs $21.6M.","Cash and marketable securities $409.4M, down from $505.0M at Dec 31, 2022; expects to fund ops into mid-2026.","R&D expense $29.7M (down 30% YoY) due to bempegaldesleukin wind-down; restructuring charges $16.6M.","Plans Phase 2b study of rezpegaldesleukin in atopic dermatitis; initial data in H1 2025; IND submission in 2024.","Corrected rezpegaldesleukin efficacy data previously miscalculated by Eli Lilly; evaluating NKTR-255 partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-064560","json":"https://secwatch.observer/filing/0001213900-23-064560.json","markdown":"https://secwatch.observer/filing/0001213900-23-064560.md","text":"https://secwatch.observer/filing/0001213900-23-064560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390023064560/0001213900-23-064560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390023064560/ea183032-8k_nektarther.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:28:55.010094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef99c5ca0a29d038cdb868726fbd5d654f96ed44","claim":"NEKTAR THERAPEUTICS reported the second quarter ended June 30, 2023 results: revenue $20.5 million, net income $51.1 million or $0.27 basic and diluted loss per share, EPS $0.27 basic and diluted loss per share.","evidence_excerpt":"our Phase 2 studies of NKTR-255 in liquid and solid tumors as we evaluate strategic partnership pathways.” Summary of Financial Results Revenue in the second quarter of 2023 was $20.5 million as compared to $21.6 million in the second quarter of 2022. Revenue for the first half of 2023 was $42.1 million as compared to $46.4 million in the first half of 2022. Total","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390023064560/0001213900-23-064560-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$20.5 million"},{"label":"Net income","value":"$51.1 million or $0.27 basic and diluted loss per share"},{"label":"EPS","value":"$0.27 basic and diluted loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}